NYLIM
ALGS icon

New York Life Investment Management’s Aligos Therapeutics ALGS Stock Holding History

New York Life Investment Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,553
Closed -$251K – 1204
2022
Q4 		$251K Buy
10,553
+1,189
+13% +$30K ﹤0.01% 1151
2022
Q3 		$258K Buy
9,364
+688
+8% +$22.8K ﹤0.01% 1140
2022
Q2 		$262K Buy
+8,676
New +$295K ﹤0.01% 1190

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York Life Investment Management's ALGS Position: Q1 2023 in Review

New York Life Investment Management sold out of Aligos Therapeutics (ALGS) in Q1 2023, closing a stake of 10,553 shares — an estimated $251K sold.

New York Life Investment Management first reported a position in ALGS in Q2 2022 and held it in 3 quarters. The position peaked at $262K in Q2 2022. 45 funds tracked by Wall St. Rank hold ALGS as of Q1 2023.

  • New York Life Investment Management reported no remaining Aligos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 10,553 Aligos Therapeutics shares in Q1 2023, an estimated $251K.
  • New York Life Investment Management first reported a position in Aligos Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Aligos Therapeutics position peaked at $262K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.